Listed by the USPTO as VALENROD, YEVGENY
Tech Center 1600 • Art Units: 1621 1625 1628 1672
This examiner grants 72% of resolved cases
VALENROD, YEVGENY has 1030 resolved cases in tech center 1600 and art unit 1621. The allowance rate is 72.5%, the interview lift is 25.1%, and the median time to allowance is 933 days. The substantial case volume shows allowance in a clear majority of matters. Interviews are associated with a meaningful but smaller improvement, while the median indicates a prosecution period of more than two years.
The principal companies are Amazentis SA, The Ohio State University, and Antecip Bioventures II LLC. The leading firms are FOLEY HOAG, LLP, PROCOPIO, CORY, HARGREAVES & SAVITCH LLP, and BIRCH STEWART KOLASCH & BIRCH, LLP. Applicants may combine technically focused interviews with disciplined written prosecution and realistic timing expectations.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18839055 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF TLR9 | Non-Final OA | Bristol-Myers Squibb Company |
| 18687599 | Dosing Regimen for a TEAD inhibitor | Non-Final OA | Novartis AG |
| 18290630 | AUTOMATED SYNTHESIS OF POLYMERIC DRUGS | Non-Final OA | SONY GROUP CORPORATION |
| 18848613 | PHARMACEUTICAL COMBINATIONS AND METHODS OF USE OF AMINO-PYRROLOPYRIMIDINONE COMPOUND | Non-Final OA | Ohio State Innovation Foundation |
| 18703008 | ARYLIMIDAMIDES FOR USE IN TREATMENT OF CANCERS | Non-Final OA | Ohio State Innovation Foundation |
| 18613203 | Small Molecule Targeting of BRD4 for Treatment of COVID-19 | Final Rejection | Board of Regents, The University of Texas System |
| 18565626 | METHODS OF TREATMENT | Final Rejection | Arena Pharmaceuticals, Inc. |
| 18682755 | BICYCLIC FUSED PYRAZOLE DERIVATIVES FOR THE TREATMENT OF RESPIRATORY INFECTIONS INCLUDING RSV | Non-Final OA | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. |
| 18541733 | SELECTIVE CDK 4/6 INHIBITOR CANCER THERAPEUTICS | Final Rejection | LUNELLA BIOTECH, INC. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy72.5% of resolved applications examined by Yevgeny Valenrod were allowed (1,030 resolved cases), compared with 46.0% across Art Unit 1621 over the last five years.
This examiner's interview lift is +25.1 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Yevgeny Valenrod took 933 days on average from filing to allowance.
Yevgeny Valenrod examines applications in Art Unit 1621 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
